Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 13, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The only material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on September 8, 2006. The number of Ordinary Share ADRs held by the fund increased from 17,338,730 to 17,381,351. This transaction occurred at an average price of $54.76.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are potentially interested in the shares held in the fund in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- The increase in ADR holdings (42,621 shares) was driven by a fund movement, not a direct purchase by the directors.
- Directors Dr. J P Garnier and Dr. M M Slaoui hold potential interests in the fund shares alongside other employees.
- The average transaction price for the fund movement was $54.76.
- This filing does not reflect the company's operational or financial results for the period.